More recently, data were presented from the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial in which patients with early-stage HER2+ breast cancer were randomized to receive adjuvant chemotherapy with trastuzumab, chemotherapy with concurrent trastuzumab and lapatinib, or chemotherapy with sequential trastuzumab and lapatinib (74). The gene discussed is ERBB2; the disease is breast cancer.